Login to Your Account



Phase II data keep DBV's Viaskin peanut allergy therapy on track

By Cormac Sheridan
Staff Writer

Monday, March 7, 2016

DUBLIN – DBV Technologies SA reported further progress from its patch-based peanut allergy therapy, Viaskin Peanut, at the American Academy of Allergy, Asthma and Immunology congress in Los Angeles over the weekend.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription